Product
TransCon PTH
2 clinical trials
3 indications
Indication
HypoparathyroidismIndication
Endocrine System DiseasesIndication
Parathyroid DisordersClinical trial
PaTHway TRIAL: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial, With an Open-Label Extension, Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Subcutaneously Daily in Adults With HypoparathyroidismStatus: Active (not recruiting), Estimated PCD: 2022-01-12
Clinical trial
PaTH Forward: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial With an Open-Label Extension, Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Subcutaneously Daily in Adults With HypoparathyroidismStatus: Active (not recruiting), Estimated PCD: 2020-03-06